p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial
暂无分享,去创建一个
H. Bruining | T. Butler | K. Kudsk | W. Lesslauer | E. Abraham | P. Laterre | M. Glauser | J. Garbino | C. Zwingelstein | D. Gelmont | E. Tobin | A. Leighton | C. Otto
[1] J. Carlet,et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.
[2] S. Opal,et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.
[3] S. Willatts,et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.
[4] S. Calvano,et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. , 1996, Journal of immunology.
[5] S. Banks,et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. , 1995, Journal of immunology.
[6] G. Ramsay,et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. , 1995, JAMA.
[7] G. Koch,et al. Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .
[8] H. Loetscher,et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram- negative sepsis , 1994, The Journal of experimental medicine.
[9] R. Bone,et al. Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.
[10] C J Fisher,et al. The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. , 1993, JAMA.
[11] J. Singer,et al. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. , 1993, Chest.
[12] A. Chang,et al. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. , 1992, The Journal of trauma.
[13] R. Wenzel. Anti-endotoxin monoclonal antibodies--a second look. , 1992, The New England journal of medicine.
[14] B. Aggarwal,et al. Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptors. , 1992, Biochemical and biophysical research communications.
[15] D. Goeddel,et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[16] B. Beutler,et al. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity , 1991, The Journal of experimental medicine.
[17] H. Tabuchi,et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethality , 1991, European journal of immunology.
[18] J. Parrillo. Management of septic shock: present and future. , 1991, Annals of internal medicine.
[19] C. Sprung,et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .
[20] F. Ognibene,et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. , 1990, Annals of internal medicine.
[21] T. van der Poll,et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.
[22] S. Opal,et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. , 1990, The Journal of infectious diseases.
[23] A. Chang,et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). , 1990, Circulatory shock.
[24] E. A. Havell. Evidence that tumor necrosis factor has an important role in antibacterial resistance. , 1989, Journal of immunology.
[25] K. Tracey,et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.
[26] T. Clemmer,et al. Sepsis syndrome: a valid clinical entity , 1989 .
[27] A. Cerami,et al. Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.
[28] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.
[29] D. Newell,et al. In pursuit of evidence based integrated care , 1987, British Journal of Cancer.
[30] T. Clemmer,et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.
[31] D Greenwood,et al. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. , 1987, The Quarterly journal of medicine.
[32] L. Jl. Gram-negative sepsis. , 1976, Delaware medical journal.
[33] R. Tompkins,et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. , 1990, The Journal of infectious diseases.